Clinical Nurse Specialist in Wallingford, CT Accepting Medicare

6 Clinical Nurse Specialist nurses found. Showing 1 - 6

Kathryn E Macary, APRN Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: 67 Masonic Ave, 1st Floor, Wallingford, CT 06492 Phone: 203-265-5720    Fax: 203-679-5623

Brian Geyser, APRN Clinical Nurse Specialist - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 51 Old Village Cir, Wallingford, CT 06492 Phone: 203-915-0524

Bonnie M Piascyk, APRN Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: 67 Masonic Ave, 1st Floor, Wallingford, CT 06492 Phone: 203-265-5720    Fax: 203-679-5623

Patty Elaine Harris, A.P.R.N. Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: 116 S. Main Street, Wallingford, CT 06492 Phone: 203-265-3347    Fax: 203-265-3651

Pamela M Sisson, APRN Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 97 Barnes Rd, Ste 2 Pyramid Primary Care Physicians Pc, Wallingford, CT 06492 Phone: 203-265-0355    Fax: 203-265-7413

Blanche C. Agostinelli, APRN Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: 67 Masonic Ave, Wallingford, CT 06492 Phone: 203-265-5720    Fax: 203-679-5623

News Archive

GSK, XenoPort disappointed with GSK1838262/XP13512 phase 2b study for migraine headaches

GlaxoSmithKline and XenoPort, Inc. announced today that GSK1838262/XP13512 (gabapentin enacarbil) did not demonstrate a statistically significant improvement compared to placebo as a prophylactic treatment for migraine headaches. This phase 2b dose-ranging study evaluated the efficacy, safety and tolerability of GSK1838262 in adults diagnosed with migraine headache (with or without aura) according to the International Headache Society criteria.

Study contradicts USA warning that an antidepressant can cause congenital abnormalities

A study carried out by German researchers has failed to show that a popular antidepressant, paroxetine, causes congenital abnormalities if taken by pregnant women, the 22nd annual conference of the European Society of Human Reproduction and Embryology heard.

Study explores how nurses make sense of racism in healthcare practice

Few studies have explored health professionals' understanding of racism in healthcare, and how they manage it in practice. A new Journal of Advanced Nursing study examined the issue through five focus group discussions with 31 maternal, child, and family health nurses working across metropolitan South Australia.

Clinical trial planned in Australia and the USA to help patients with ‘orphan' disease

Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington's patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington's often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.

Read more Medical News

› Verified 3 days ago